As an oncogene, overexpression of SOX2 is linked to increased cellular replication rates, aggressive tumor grades and poor patient outcomes in breast carcinoma (BRCA) (41–45), colon adenocarcinoma (COAD) (46–49), glioblastoma (GBM) (50–53), liver hepatocellular carcinoma (LIHC) (54), lung adenocarcinoma (LUAD) (55–57) and lung squamous cell carcinoma (LUSC) (58,59). This evidence concerns the gene SOX2 and lung adenocarcinoma.